The Outcome of Six Patients with COVID-19 Infection and Multiple Myeloma. A Case Series and Literature Review COVID-19 in Multiple Myeloma patients

Main Article Content

Hesham Elsabah
Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC) Doha, Qatar.

Mahmood B. Aldabt
1. Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC) Doha, Qatar.

Ruba Taha
1. Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC) Doha, Qatar.

Dina Sameh Soliman
Department of Laboratory Medicine andPathology, National Center for Cancer Careand Research, Hamad Medical Corporation,PO Box 3050, 16060 Doha, Qatar.E-mail:

Halima Elomri
1. Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC) Doha, Qatar.

Feryal Ibrahim
2. Department of Laboratory Medicine and Pathology, National Centre for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar.

Keywords

COVID-19, Multiple myeloma (MM), ARDS (acute respiratory distress syndrome), Interlukin6 (IL-6), Tocilizumab.

Abstract

No abstract, as A letter to the Editor.

Downloads

Download data is not yet available.


Abstract 602
PDF Downloads 248
HTML Downloads 75

References

References
1. World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed on February 12, 2020).
2. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-95. doi:10.1016/j.ijid.2020.03.017
3. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China [published online ahead of print, 2020 Mar 25]. JAMA Oncol. 2020;6(7):1108-1110. doi:10.1001/jamaoncol.2020.0980
4. El-Sharkawi D, Iyengar S. Haematological cancers and the risk of severe COVID-19: Exploration and critical evaluation of the evidence to date [published online ahead of print, 2020 Jun 19]. Br J Haematol. 2020;10.1111/bjh.16956. doi:10.1111/bjh.16956
5. Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107-113. doi:10.3324/haematol.2014.107714
6. Dhakal, B., D’Souza, A., Chhabra, S. et al. Multiple myeloma and COVID-19 Leukemia. (2020) 34:1961–1963 https://doi.org/10.1038/s41375-020-0879-9
7. K Gadó , G Domján, H Hegyesi. ROLE OF INTERLEUKIN-6 IN THE PATHOGENESIS OF MULTIPLE MYELOM. Cell Biology International Volume 24, Issue 4, April 2000, Pages 195-209
8. Pan Luo | Yi Liu | Lin Qiu | Xiulan Liu | Dong Liu | Juan Li .Tocilizumab treatment in COVID?19: A single center experience J Med Virol. 2020,92:814-818.DOI: 10.1002/jmv.25801

9. Giovanni Guaraldi*, Marianna Meschiari*, Alessandro Cozzi-Lepri, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The lancet.com/rheumatology. 2020 , Vol 2,issue 8,E474-E484

10. A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA) ClinicalTrials.gov Identifier: NCT04320615

11. Hoffman-La Roche. A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia (REMDACTA). June 2020. Available at https://clinicaltrials.gov/ct2/show/NCT04409262. Accessed on June 1, 2020.

12. Genentech. A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants with COVID-19 Pneumonia. May 2020. Available at https://clinicaltrials.gov/ct2/show/NCT04372186. Accessed on May 18, 2020.

13. Zhang X, Song K, Tong F, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020;4(7):1307-1310.

14. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020;19(6):102537. doi:10.1016/j.autrev.2020.102537

Article Sidebar

PDF HTML
Published
Oct 27, 2020
DOI https://doi.org/10.4084/mjhid.2020.082

Article Details

How to Cite

Elsabah, . H. . (2020) “The Outcome of Six Patients with COVID-19 Infection and Multiple Myeloma. A Case Series and Literature Review: COVID-19 in Multiple Myeloma patients”, Mediterranean Journal of Hematology and Infectious Diseases, 12(1), p. e2020082. doi: 10.4084/mjhid.2020.082.
Issue
Vol. 12 No. 1 (2020): Mediterranean Journal of Hematology and Infectious Diseases, Volume 12, 2020
Section
Letters to the Editor
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.